Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:ORTX

Orchard Therapeutics (ORTX) Stock Price, News & Analysis

Orchard Therapeutics logo

About Orchard Therapeutics Stock (NASDAQ:ORTX)

Advanced Chart

Key Stats

Today's Range
$16.70
$16.70
50-Day Range
$16.40
$16.70
52-Week Range
$4.24
$16.72
Volume
N/A
Average Volume
157,287 shs
Market Capitalization
$380.09 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive ORTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Orchard Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ORTX Stock News Headlines

Banks aren’t ready for this altcoin—are you?
Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly positioned to fill it…
See More Headlines

ORTX Stock Analysis - Frequently Asked Questions

Orchard Therapeutics plc (NASDAQ:ORTX) issued its quarterly earnings results on Monday, May, 15th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.61) by $1.49. The business had revenue of $1.24 million for the quarter, compared to analyst estimates of $6.48 million. Orchard Therapeutics had a negative net margin of 333.90% and a negative trailing twelve-month return on equity of 74.94%.

Orchard Therapeutics's stock reverse split on the morning of Friday, March 10th 2023.The 1-10 reverse split was announced on Friday, March 10th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, March 10th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Orchard Therapeutics (ORTX) raised $200 million in an initial public offering on Wednesday, October 31st 2018. The company issued 13,300,000 shares at $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that Orchard Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), Jabil (JBL) and e.l.f. Beauty (ELF).

Company Calendar

Last Earnings
5/15/2023
Today
7/04/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:ORTX
Previous Symbol
NASDAQ:ORTX
Fax
N/A
Employees
166
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$150.66 million
Net Margins
-333.90%
Pretax Margin
-334.54%

Debt

Sales & Book Value

Annual Sales
$22.66 million
Price / Cash Flow
N/A
Book Value
$7.74 per share
Price / Book
2.16

Miscellaneous

Free Float
22,099,000
Market Cap
$380.09 million
Optionable
Optionable
Beta
0.55
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

This page (NASDAQ:ORTX) was last updated on 7/5/2025 by MarketBeat.com Staff
From Our Partners